Literature DB >> 30197068

Consultation for Elevated Blood Eosinophils: Clinical Presentations, High Value Diagnostic Tests, and Treatment Options.

Paneez Khoury1, Bruce S Bochner2.   

Abstract

The workup of a patient found to have eosinophilia should follow a thorough path with a detailed history and physical examination aimed at eliciting eosinophilic organ involvement, followed by histological confirmation whenever possible. The differential diagnosis of hypereosinophilia is extensive, but a rational approach beyond the history and physical examination including serologic, blood, and bone marrow cell analyses, genetic testing, and radiologic imaging can distinguish many of the causes. Often input from specialists (eg, hematology, dermatology, pulmonary, gastroenterology, and neurology) can help narrow down the possibilities and eventually result in a specific diagnosis. An accurate diagnosis is key to choosing the optimal treatment for a particular condition, and this is certainly true for eosinophilic disorders. Myeloid neoplasms that present with eosinophilia, for example, may respond to medicines that the allergist may be less accustomed to using, such as immunosuppressive agents and kinase inhibitors. Similarly, newly approved biologics that target IL-5 and eosinophils may provide new options for management. What follows is a case-based approach that helps to underscore key features of diagnosis, management, and follow-up when faced with a patient with a potential eosinophil-related disorder.
Copyright © 2018 American Academy of Allergy, Asthma & Immunology. All rights reserved.

Entities:  

Keywords:  Diagnosis; Eosinophilia; Hypereosinophilic syndromes; Testing; Treatment

Mesh:

Substances:

Year:  2018        PMID: 30197068      PMCID: PMC6258010          DOI: 10.1016/j.jaip.2018.04.030

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  51 in total

1.  Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.

Authors:  Elisa Rumi; Jelena D Milosevic; Dominik Selleslag; Ilaria Casetti; Els Lierman; Daniela Pietra; Chiara Cavalloni; Marta Bellini; Chiara Milanesi; Irene Dambruoso; Cesare Astori; Robert Kralovics; Peter Vandenberghe; Mario Cazzola
Journal:  Ann Hematol       Date:  2015-07-23       Impact factor: 3.673

2.  Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management.

Authors:  Matthieu Groh; Christian Pagnoux; Chiara Baldini; Elisabeth Bel; Paolo Bottero; Vincent Cottin; Klaus Dalhoff; Bertrand Dunogué; Wolfgang Gross; Julia Holle; Marc Humbert; David Jayne; J Charles Jennette; Romain Lazor; Alfred Mahr; Peter A Merkel; Luc Mouthon; Renato Alberto Sinico; Ulrich Specks; Augusto Vaglio; Michael E Wechsler; Jean-François Cordier; Loïc Guillevin
Journal:  Eur J Intern Med       Date:  2015-05-09       Impact factor: 4.487

Review 3.  Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis.

Authors:  J H Butterfield
Journal:  Acta Haematol       Date:  2005       Impact factor: 2.195

4.  Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness.

Authors:  Amy D Klion; Pierre Noel; Cem Akin; Melissa A Law; D Gary Gilliland; Jan Cools; Dean D Metcalfe; Thomas B Nutman
Journal:  Blood       Date:  2003-04-03       Impact factor: 22.113

Review 5.  Biologic Agents for the Treatment of Hypereosinophilic Syndromes.

Authors:  Fei Li Kuang; Amy D Klion
Journal:  J Allergy Clin Immunol Pract       Date:  2017 Nov - Dec

6.  Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.

Authors:  Christoph Walz; Philipp Erben; Michael Ritter; Adrian Bloor; Georgia Metzgeroth; Nick Telford; Claudia Haferlach; Torsten Haferlach; Stefan Gesk; Joannah Score; Wolf-Karsten Hofmann; Andreas Hochhaus; Nicholas C P Cross; Andreas Reiter
Journal:  Blood       Date:  2011-06-24       Impact factor: 22.113

Review 7.  Eosinophilia in Rheumatologic/Vascular Disorders.

Authors:  Hiromichi Tamaki; Soumya Chatterjee; Carol A Langford
Journal:  Immunol Allergy Clin North Am       Date:  2015-06-17       Impact factor: 3.479

8.  Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.

Authors:  Michael E Wechsler; Praveen Akuthota; David Jayne; Paneez Khoury; Amy Klion; Carol A Langford; Peter A Merkel; Frank Moosig; Ulrich Specks; Maria C Cid; Raashid Luqmani; Judith Brown; Stephen Mallett; Richard Philipson; Steve W Yancey; Jonathan Steinfeld; Peter F Weller; Gerald J Gleich
Journal:  N Engl J Med       Date:  2017-05-18       Impact factor: 91.245

9.  Treatment of patients with the hypereosinophilic syndrome with mepolizumab.

Authors:  Marc E Rothenberg; Amy D Klion; Florence E Roufosse; Jean Emmanuel Kahn; Peter F Weller; Hans-Uwe Simon; Lawrence B Schwartz; Lanny J Rosenwasser; Johannes Ring; Elaine F Griffin; Ann E Haig; Paul I H Frewer; Jacqueline M Parkin; Gerald J Gleich
Journal:  N Engl J Med       Date:  2008-03-16       Impact factor: 91.245

10.  Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.

Authors:  Sally Wenzel; Mario Castro; Jonathan Corren; Jorge Maspero; Lin Wang; Bingzhi Zhang; Gianluca Pirozzi; E Rand Sutherland; Robert R Evans; Vijay N Joish; Laurent Eckert; Neil M H Graham; Neil Stahl; George D Yancopoulos; Mariana Louis-Tisserand; Ariel Teper
Journal:  Lancet       Date:  2016-04-27       Impact factor: 79.321

View more
  7 in total

1.  Pediatric Hypereosinophilia: Characteristics, Clinical Manifestations, and Diagnoses.

Authors:  Dara Burris; Chen E Rosenberg; Justin T Schwartz; Yin Zhang; Michael D Eby; J Pablo Abonia; Patricia C Fulkerson
Journal:  J Allergy Clin Immunol Pract       Date:  2019-05-22

Review 2.  Contributions of Eosinophils to Human Health and Disease.

Authors:  Amy D Klion; Steven J Ackerman; Bruce S Bochner
Journal:  Annu Rev Pathol       Date:  2020-01-24       Impact factor: 23.472

Review 3.  [Differential diagnosis of hypereosinophilia].

Authors:  J C Henes; S Wirths; B Hellmich
Journal:  Z Rheumatol       Date:  2019-05       Impact factor: 1.530

4.  Next-generation sequencing specifies Angiostrongylus eosinophilic meningoencephalitis in infants: Two case reports.

Authors:  Mei Xie; Zhen Zhou; Suhua Guo; Zengqing Li; Hui Zhao; Jiusheng Deng
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

5.  Single-site, five-year experience with human eosinophil isolation by density gradient centrifugation and CD16 immunomagnetic negative separation.

Authors:  Yun Cao; Sooncheon Shin; Daniela J Carroll; Jeremy A O'Sullivan; Bruce S Bochner
Journal:  BMC Res Notes       Date:  2020-04-10

Review 6.  Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity.

Authors:  Peter Valent; Lina Degenfeld-Schonburg; Irina Sadovnik; Hans-Peter Horny; Michel Arock; Hans-Uwe Simon; Andreas Reiter; Bruce S Bochner
Journal:  Semin Immunopathol       Date:  2021-05-30       Impact factor: 9.623

Review 7.  Gene Expression Comparison between Sézary Syndrome and Lymphocytic-Variant Hypereosinophilic Syndrome Refines Biomarkers for Sézary Syndrome.

Authors:  Andrea Moerman-Herzog; Syed J Mehdi; Henry K Wong
Journal:  Cells       Date:  2020-08-29       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.